NCT07140016 2026-03-04
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Inc
Phase 1 Recruiting
Clinical Trials
3 trialsNCT06225427 2025-10-20
Gilteritinib for the Treatment of ALK NSCLC
University of Michigan Rogel Cancer Center
Phase 1 Recruiting
NCT02495233 2024-11-27
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Astellas Pharma Inc
Phase 1/2 Terminated